Oskar Hansson, M.D., Ph.D.

Principal Investigator, Professor, Research Team Manager, Clinical Memory Research, Lund University, Sweden

Dr. Oskar Hansson gained his Ph.D. in neurobiology in 2001 and his M.D. in 2005. He became a senior consultant in neurology in 2012 at Skåne University Hospital, and a full professor of neurology in 2017 at Lund University, Sweden. Oskar Hansson performs internationally recognized clinical and translational research focusing on the early phases of Alzheimer’s and Parkinson’s diseases. His work on biomarkers has led to over 350 original peer-reviewed publications. He heads the prospective and longitudinal Swedish BioFINDER studies (www.biofinder.se), where the research team focuses on the development of optimized diagnostic algorithms for early diagnosis, and also studies the consequences of different brain pathologies on cognitive, neurologic, and psychiatric symptoms in healthy individuals and patients with dementia and parkinsonian disorders. Recently, the BioFINDER team has shown that Tau PET imaging can reliably distinguish Alzheimer’s from other neurodegenerative diseases (JAMA, 2018) and to detect different subtypes of Alzheimer’s (Nature Medicine 2021), and the team has validated blood-based biomarkers for early detection of Alzheimer’s disease (Nature Medicine, 2020; JAMA, 2020, Nature Aging 2021, Nature Medicine 2021). He is the co-director of the strategic research area of neuroscience at Lund University, and responsible for research at the Memory Clinic at Skåne University Hospital.

@RikOssenkoppele, @biofinder_study


Funded Research

These projects were made possible from Cure Alzheimer's Fund support.